Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.76 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20758423 | 1.00 | HTR6 (0.76) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL16108748 | 0.98 | HTR6 (0.73) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL20744604 | 0.98 | HTR6 (0.79) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL2328636 | 0.98 | HTR6 (0.79) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL16110108 | 0.95 | HTR6 (0.76) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL16110110 | 0.95 | HTR6 (0.76) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL16110484 | 0.95 | HTR6 (0.76) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL25687891 | 0.93 | HTR6 (0.80) | HTR6HTR2BL3MBTL3L3MBTL1KMT2A | |
| SCHEMBL20744481 | 0.93 | HTR6 (0.72) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL12730878 | 0.93 | HTR6 (0.72) | HTR6SLC6A1SLC6A11TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4138824-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | Anovia Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| CN-108246113-A | A kind of preparation method of big flux complex reverse osmosis membrane | 深圳市海通膜科技有限公司 | 2018-07-06 | — | — | CN | claimed |
| CN-105435653-B | A kind of composite nanometer filtering film to divalent ion removing with high selectivity and preparation method thereof | 贵阳时代沃顿科技有限公司 | 2018-02-06 | — | — | CN | claimed |
| CN-106621850-A | Antibacterial composite nanofiltration membrane, and preparation method and application thereof | 中国石油化工股份有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4352048-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2024-04-17 | — | — | EP | disclosed |
| CN-117480162-A | Compounds for the treatment or prophylaxis of PRMT5 mediated diseases | 阿古诺治疗有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022258986-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2022-12-15 | — | — | WO | disclosed |
| CN-108176241-A | A kind of composite nanometer filtering film containing aquaporin and preparation method thereof | 博通分离膜技术（北京）有限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-105080367-B | A kind of composite nanometer filtering film containing composite nanoparticle and preparation method | 中国石油化工股份有限公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-105080358-B | A kind of reverse osmosis composite membrane and preparation method containing organically-modified attapulgite | 中国石油化工股份有限公司 | 2017-11-07 | — | — | CN | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| EP-0287696-B1 | ISOQUINOLINE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
| EP-0287696-A1 | Isoquinoline derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | HTR6 169/4885SLC6A1 440/4885SLC6A11 405/4885 |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | HTR6 422/4885SLC6A1 398/4885SLC6A11 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.